novarti gene therapi spinal muscular atrophi sma zolgensma
key investor focu ahead expect fda approv late may
report set model assumpt also address key
sensit around breadth label price
sma highli debilit rare genet diseas caus lack
function surviv motor neuron gene sever vari base
number back-up copi gene sever form type
babi need perman breath support die age
base case net price assumpt per patient us
per patient ex-u note health econom data support
price per patient provid sensit price estim
price would increas npv respect
base case assum us approv symptomat type sma
age limit month dose essenti captur annual
incid patient popul sma type underpin peak sale
potenti launch assum rapid ramp peak sale
base case total peak sale potenti group npv
launch diagnos genet test birth us birth
screen sma birth today would add modest npv
simpli bring forward opportun year
time assum intrathec zolgensma approv
older type sma patient strong data matur
unlock preval patient popul addit peak sale
blue sky scenario could see approv launch feel unlik
valuat novarti trade ep premium eu
peer stock trade premium npv ahead eu peer
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novarti provid healthcar solut compani
multi-national group compani special research
develop manufactur market rang healthcar
product led pharmaceut
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
scenario base pipelin success
higher peak sale cosentyx stronger sandoz
biopharma revenu gilenya patent life
extens
grey scenario base pipelin success lower
peak sale entresto lower cosentyx peak sale
lower sandoz growth
price rel chart measur perform swiss market
ind close
spot exchang rate
zolgensma sma
spinal muscular atrophi sma rare genet diseas lead irrevers loss
motor neuron follow birth rapidli affect muscl function sma infant
fail develop normal motor movement develop mileston head control
sit stand crawl sever patient need perman breath support
die infanc
sma caus lack function surviv motor neuron gene
sever symptom vari due number copi back-up gene
patient may approxim activ
figur set classif sma type expect symptom
motor neuron function lost month age babi requir
perman breath support die age two sma type repres patient
incid type type incid patient
zolgensma single-dos gene therapi use adeno-associ viru
viral vector introduc function gene patient
gene integr patient dna remain stabl vector
cell infant born motor neuron rare divid earli administr
zolgensma potenti provid express life howev
durabl benefit remain key question time answer recent
updat phase start studi patient retain motor mileston year
zolgensma administ singl inject infant patient less month
old heaviest babi studi administ intraven inject
transgen cross blood brain barrier enter spinal cord
older patient higher dose therapi need ensur good distribut
gene given patient larger bodi mass safeti toler high
dose viral vector explor patient zolgensma
administ singl inject spinal cord intrathec administr
ensur direct access lower dose zolgensma motor neuron
advent sma genet screen birth
juli us health human servic hh secretari azar approv
addit sma list condit recommend newborn screen us
follow hh recommend individu state respons implement
date minnesota missouri new york pennsylvania utah routin screen
newborn sma addit state process exampl
florida commit state-wid screen august recent investor call
novarti highlight us birth cover genet screen
novarti note pilot newborn sma screen program also
consider number ex-u countri
newborn screen offer opportun identifi sma patient type within
age rang intraven zolgensma shown effect novarti
studi presymptomat patient group trial posit interim data
present may novarti state interim data
share fda consequ potenti
approv zolgensma could includ all-com sma identifi genet screen
birth consid potenti sensit analysi
model sensit zolgensma
price therapi
price first commerci gene therapi clearli break new ground industri
key sensit zolgensma model
us best support care estim cost per year sma type
list price current standard care spinraza cost year load
dose treatment dose per year thereaft base five-year treatment
window spinraza cost scotland exampl ex-u price
equival price spinraza discount us
zolgensma administ singl dose retreat assum
us conserv assum one-tim net treatment cost per patient
zolgensma ex-u assum annual payment per patient
durat clinic benefit product assum maximum year treatment
cost total per patient ex-u midterm distribut cost therapi
easier imagin within single-pay environ ex-u limit up-front cost
therapi health author note novarti also explor staged-pay
model us market previou high-cost cancer therapi
april us institut clinic econom review icer issu final
evid report cost effect sma therapi link icer assum base-
case price zolgensma analysi also conclud price
per patient could justifi use highest threshold level per quality-
figur figur set revenu npv sensit implic base
differ zolgensma price point use base case label model see
also flex npv new probabl success see figur base assum
approv type incid patient model
figur equiti npv sensit zolgensma price
charl martineau univers toronto figur chang probabl success first approv zolgensma
probabl success
breadth zolgensma label launch
novarti pursu zolgensma number patient subgroup sma younger
patient trial month age zolgensma administ
intraven infus older patient zolgensma administ inject
spinal cord intrathec reduc dose requir thu lower risk high
dose viral vector exposur differ formul trial allow number
distinct patient popul label view
sma type incid newli diagnos patient sever form
sma vast major diagnos month age base
symptom would also identifi genet screen birth
implement incid patient popul reload everi year base overal
rate new birth
sma type preval patient previous diagnos either untreat
today treat spinraza mani like exceed month age threshold
limit clinic trial iv dose patient like
need approv intrathec dose access zolgensma preval patient
popul repres bolu revenu potenti top regular incid use
sma type incid newli diagnos patient less sever
type form sma major diagnos symptom
month age consequ also need wait intrathec dose
approv howev advent genet screen birth could provid access
patient group age would avail iv dose potenti
support trial posit interim data present
incid patient popul reload everi year
sma type preval patient previous diagnos milder
form either untreat treat spinraza patient need intrathec
dose live rel long time repres larg bolu
patient may elig zolgensma time
zolgensma initi label expect intraven admin type month
base case assum approv iv dose zolgensma patient less
month age would provid access vast major type incid patient
assum intrathec approv provid access
subgroup revenu trajectori base base case us net price
assumpt set figur
assum sale potenti us revenu peak
scenario bolu preval patient address plateua annual
revenu base incid patient rate
addit approv pre-symptomat patient
bull case assum dynam base case howev also includ
approv pre-symptomat patient diagnos base genet test birth
would also allow access iv formul type patient state
introduc mandatori genet test novarti believ us birth
current screen sma bull case add type incid revenu
potenti launch modest impact increas sale
type incid opportun brought forward
simultan approv intrathec admininistr older children
scenario assum simultan approv zolgensma iv intrathec
dose launch would provid access patient group may
feel unlik scenario due limit safeti experi intrathec
dose recognis fda opportun review on-going clinic
trial data sma highli debilit diseas
scenario revenu increas peak sale move forward
bolu preval patient address earlier
npv impact label breadth
figur set npv sensit label breadth launch step current
base case reflect probabl type incid patient approv flex
scenario neither bull case materi impact npv
bring forward opportun alreadi includ model
figur equiti npv sensit zolgensma label breadth price
zolgensma therapi sma import consid broader
market main scope report figur set cs
expect roche/ptc risdiplam evalu consensu expect
biogen spinraza drug aim increas level activ smn protein cell
modifi gene express splice patient gene need
dose regularli life rel one done assumpt zolgensma
administr see scope mode action market base
see efficaci comparion three product broadli similar base
limit patient number divers small patient popul publish date
long-term follow larger studi may reveal efficaci differ time
longer term safeti profil spinraza launch appeal
patient develop antibodi natur occur adeno-associ
viru aav thu like elig zolgensma estim vari
popul low high singl digit percentag patient risk greater
base age patient time accumul natur immun
see signifc potenti risdiplam preval type patient popul
given simpl oral dose regim solid efficaci date
time see wane benefit gene therapi time
risdiplam/spinraza potenti furhter supplement smn protein product
older children time tell durat benefit gene therapi
proof concept
 novarti
novarti premium/ discount eu
novarti premium/ discount global
basic number share
fulli dilut number share
compani mention price
